Atrial Fibrillation Background information for medical media outside the US only This selection gives an overview on background material for the Atrial Fibrillation available on the Boehringer Ingelheim corporate website.

News Releases

• 30 August 2009Groundbreaking results in the RE-LY® trial - novel oral direct thrombin inhibitor dabigatran etexilate convincingly beats warfarin - superior stroke reduction with less bleeding!
• 20 March 2009Boehringer Ingelheim's novel oral anticoagulant dabigatran etexilate is the frontrunner for stroke prevention in atrial fibrillation: final patient completes treatment in the RE-LY® study, the largest atrial fibrillation outcomes trial to date
• 11 November 2008Longest follow-up period for any new oral anticoagulant explores Pradaxa® (dabigatran etexilate) for stroke prevention in atrial fibrillation (AF) Latest results in anticipation of Boehringer Ingelheim's RE-LY® study, the largest stroke prevention in AF trial to date
• news release archive

Documents

• Backgrounder: RE-LY® Study - 30 August 2009 - PDF (189 KB)
• Backgrounder: Pradaxa® (dabigatran etexilate) and RE-VOLUTION® - 30 August 2009
  - PDF (277 KB)
• Backgrounder: Atrial fibrillation and stroke - 30 August 2009 - PDF (292 KB)
• Backgrounder: Stroke prevention therapy for patients with atrial fibrillation - 30 August 2009
  - PDF (474 KB)
• Glossary of terms - 30 August 2009 - PDF (86 KB)

Media Resources

• On demand webcast: View the webcast from the Boehringer Ingelheim press conference at the ESC 2009 in Barcelona on 30 August.